Exhibit 99.1 For investors For media +1 858-836-5000 +1 619-510-1281 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025 • Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27% • Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, October 24, 2024 – ResMed Inc. (NYSE: RMD, ASX: RMD) today announced ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

ResMed Inc.'s (RMD) robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company's investment in digital health technology looks poised to drive growth in the upcoming quarters. However, the increasing debt burden and macroeconomic pressures on ResMed's operations remain a concern. In the past year, shares of this Zacks Rank #2 (Buy) company have surged 69.8%, out ...

Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed (RMD) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 24, 2024, might help the stock move higher if these key numbers are better than expe ...

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, ...

ResMed (RMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Individual ...

ResMed (RMD) , a leading provider of cloud-connected medical devices, has unveiled new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These include the addition of new features in myAir consumer patient engagement app, a Generative AI-enabled sleep health assistant, and travel gear to support CPAP (continuous positive airway pressure) treatment while traveling. The latest innovations capitalize on the rising popularity of digital wearables, like smartwatches and h ...

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better experience, lower costs, and enhanced outcomes for patients and providers Introduces updated five-year financial outlook NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns ...

ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world's leading health technology comp ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in ...